Elutia Inc-A 2025年季度报告

(Mark One) Elutia Inc. N/A Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15 (d)of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file suchreports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ As of May 8, 2025, there were36,802,258shares of the registrant’s Class A common stock and4,313,406shares of theregistrant’s Class B common stock outstanding. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Act of 1995. We intendsuch forward-looking statements to be covered by the safe harbor provisions for forward-lookingstatements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Allstatements other than statements of historical facts contained in this Quarterly Report, including,without limitation, statements regarding our results of operations, financial position, and businessstrategy; expectations regarding our products and their targeted effects; plans for our sales andmarketing growth; expectations regarding thepotential payment of post-closing earnout paymentsfrom the sale of our former Orthobiologics segment (the “Orthobiologics Business”) toBerkeleyBiologics, LLC (“Berkeley”);our anticipated expansion of our product development and researchactivities; increases in expenses and seasonality; expectations regarding our competitive advantages,and overall clinical and commercial success; expectations regarding the pending lawsuits and claimsrelated to our recall of a single lot of Fiber Viable Bone Matrix (“FiberCel”) and a separate single lotof viable bone matrix (“VBM”) and expectations regarding the litigation matter with MedtronicSofamor Danek USA, Inc. (“Medtronic”), amounts recoverable under insurance, indemnity andcontribution agreements and the impact of such lawsuits and claims on our future financial position;and our expectations and plans regarding pursuit of any strategic transactions are forward-lookingstatements. These statements involve known and unknown risks, uncertainties and other importantfactors that may cause our actual results, performance or achievements to be materially different fromany future results, performance or achievements expressed or implied by the forward-lookingstatements. Without limiting the foregoing, the words “aim,” “believe,” “may,” “will,” “should,”“expect,” “exploring,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”“believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms orother similar expressions, are intended to identify forward-looking statements, although not allforward-lookingstatements contain these words.These forward-looking statements are not aguarantee of future results, performance, or achievements, and one should avoid placing unduereliance on such statements. These forward-looking statements are based on our management’s beliefs and assumptionsand on information currently available to us. Such beliefs and assumptions may or may not prove tobe correct. Additionally, such forward-looking statements are subject to a number of known andunknownrisks,uncertainties and other important factors that may cause our actual results,performance or achievements to be materially different from any future results, performance orachievements expressed or implied in the forward-looking statements, including, but not limited tothe following: ●our ability to successfully commercialize, market and sell our newly approved EluPro®antibacterial envelope device;●our ability to continue as a going concern;●our ability to achieve or sustain profitability;●